financetom
Business
financetom
/
Business
/
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Jul 29, 2025 11:38 AM

Bausch Health Companies Inc. ( BHC ) on Tuesday agreed to indirectly acquire DURECT Corp ( DRRX ) , including a novel therapeutic molecule, larsucosterol.

Larsucosterol, an endogenous sulfated oxysterol and an epigenetic modulator, has demonstrated promising results for alcoholic hepatitis (AH) in Phase 2 trials.

Alcoholic hepatitis is a severe liver inflammation caused by excessive alcohol consumption. It is characterized by the rapid onset of jaundice and liver enlargement.

Bausch Health’s hepatology development and commercial capabilities are well-suited to support the clinical development and potential commercialization of larsucosterol.

The companies add that there is currently no Food and Drug Administration- or European Medicines Agency-approved treatment for AH.

Also Read: Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

Bausch Health ( BHC ) will pay $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million, with the potential for two additional net sales milestone payments of up to $350 million.

A registrational Phase 3 program to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH is being planned.

The trial will be a randomized, double-blind, placebo-controlled, multi-center study. The primary endpoint will be 90-day survival.

The trial design will incorporate feedback received from the FDA during a Type B meeting under Breakthrough Therapy Designation and learnings from the prior Phase 2b AHFIRM trial in AH.

The acquisition of the clinical development program for larsucosterol in AH complements the ongoing Bausch Health RED-C clinical program, which is designed to assess the efficacy of a next-generation therapeutic, rifaximin SSD, to delay the onset of first overt hepatic encephalopathy (OHE) hospitalization and all-cause mortality.

Patient enrollment in two global Phase 3 studies is now complete with efficacy and safety results expected to be announced in early 2026.

The transaction is expected to close in the third quarter of 2025.

Last year, Bausch Health was in talks with several private equity firms about selling Bausch + Lomb Corp ( BLCO ) .

The Bausch + Lomb ( BLCO ) spin-off was part of Bausch Health's ( BHC ) plan to alleviate its $21 billion debt, a third of which is due by 2027.

BHC, DRRX Price Actions: Bausch Health ( BHC ) stock is down 0.36% at $6.87, and DURECT ( DRRX ) stock is up 238.34% at $1.87 at publication on Tuesday.

Read Next:

UnitedHealth Misses Q2 Mark But Vows A Healthier 2026

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Banco Santander Rules out Interest in Acquiring Novo Banco
Market Chatter: Banco Santander Rules out Interest in Acquiring Novo Banco
Feb 7, 2025
09:04 AM EST, 02/07/2025 (MT Newswires) -- Banco Santander (SAN) is not interested in acquiring Portuguese financial services company Novo Banco from private equity firm Lone Star, Bloomberg reported Friday. We don't want to buy Novo Banco, Santander CEO Pedro Castro e Almeida told reporters in Lisbon, Bloomberg reported. We want to grow organically. We're very profitable. Santander and Novo...
Canadian Posts Another
Canadian Posts Another "Heady" Month of Job Creation Despite Uncertainty Over U.S. Tariffs, Says Desjardins
Feb 7, 2025
09:03 AM EST, 02/07/2025 (MT Newswires) -- Employment across Canada rose 76,000, tripling the consensus estimate for a 25,000 increase, said Desjardins following Friday's Labour Force Survey (LFS). With the strength in hiring coming despite a further slowdown in population growth, it was enough to push the unemployment rate down one tick to 6.6%, noted the bank. Adding to the...
Elliott takes $1.5 bln stake in Aspen, pushes against merger with Emerson
Elliott takes $1.5 bln stake in Aspen, pushes against merger with Emerson
Feb 7, 2025
Feb 7 (Reuters) - Activist investor Elliott Management said on Friday it has taken a more than $1.5 billion stake in Aspen Technology ( AZPN ), saying it disagrees with the company's decision to accept a tender offer by Emerson Electric ( EMR ) . ...
FedEx Extends Expiration Date for Senior Notes Exchange Offers to Feb. 21
FedEx Extends Expiration Date for Senior Notes Exchange Offers to Feb. 21
Feb 7, 2025
09:06 AM EST, 02/07/2025 (MT Newswires) -- FedEx ( FDX ) said Friday it extended the expiration date of the offers to exchange all of its outstanding senior notes of certain existing notes from Feb 6. to Feb. 21 for new notes and the related consent solicitations to adopt certain proposed amendments to each indentures governing the existing notes. Eligible...
Copyright 2023-2026 - www.financetom.com All Rights Reserved